PrioClear™ Prion Binding Affinity Adsorbents BrochureSource: ProMetic BioSciences Ltd
Scientific research estimates that there may be at least 3,800 asymptomatic vCJD carriers in the UK and in 2006 the National CJD Surveillance Unit report stated that “the incidence of vCJD may increase again, particularly if different genetic subgroups are found but with longer incubation periods”. The recent confirmation of a vCJD victim of MV genotype suggests that this is now a real possibility.
Genotype studies confirm that all the population is at risk of vCJD.
Regulatory bodies have increasingly adopted the precautionary principle with respect to both transfused blood/blood components and plasma products and recommend measures to reduce the potential risk of infectivity where possible.
A removal strategy avoids all issues of notification, verification and management of false positives that are inevitably associated with screening tests for donor deferral.